Project Mosaic

Project Mosaic is a collaborative research initiative based in Henderson, NV, aimed at revolutionizing the understanding and treatment of sporadic Amyotrophic Lateral Sclerosis (ALS). By leveraging a multi-lab approach, the initiative seeks to create more accurate models that reflect the disease's complexity, facilitating tailored treatments for patients.

Launched in 2024, Project Mosaic has made significant progress in validating shared cell lines that exhibit TDP-43 dysfunction, a critical marker of ALS. The organization is dedicated to fostering precision medicine in ALS, aiming to provide researchers and drug developers with better tools to enhance clinical trial success rates and ultimately deliver personalized therapies for patients.

Generated from the website